Skip to main content
OpenTrials
Completed

NCT Number: NCT02921906

Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes

Neonatal diabetes is diagnosed before 6 months of age and causes high blood glucose levels due to the pancreas not secreting insulin. Neonatal diabetes can be caused by a change in a DNA region called the KCNJ11 gene. KCNJ11 encodes a channel in the pancreas that acts as a switch to turn 'on' and 'off' insulin secretion. A change in KCNJ11 results in a faulty channel, which keeps insulin secretion 'switched off'. The diabetes can be treated with tablets called sulphonylureas that switch the pancreatic channel 'on', allowing it to secrete insulin in response to gut hormones called incretins. Previous research has shown that patients who switch from insulin to sulphonylureas have better blood glucose control, including fewer episodes of hypoglycaemia (glucose dropping too low), and also avoid the need for injections. It is thought that serious side effects from sulphonylureas are uncommon in KCNJ11 neonatal diabetes. Some patients report low glucose after meals and we think this may be because they make too much insulin if they eat a meal with protein but low amounts of carbohydrate. The investigators will test this by giving study participants different meals and measuring the amount of insulin, glucose and incretin hormone in the blood afterwards.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Exeter Clinical Research Facility

Exeter, Devon, EX25DW, United Kingdom

About this study

Anecdotal evidence from routine clinical care suggests that patients with sulphonylurea-treated KCNJ11 neonatal diabetes, when they eat, may experience mild hypoglycaemia if the food consumed lacks carbohydrate. It has been suggested that this may be due to regulation of insulin secretion via the incretin pathway as opposed to the classical ATP pathway. Therefore the investigators hypothesise that foods with a relatively high protein content compared to those with a relatively high carbohydrate content will result in excessive insulin secretion and relatively lower glucose values in KCNJ11 patients. This would be in contrast to healthy control subjects or subjects with SU-treated T2D where the insulin secretion will be moderated by the ambient glucose via the classical ATP pathway. The investigators will formally study this hypothesis by comparing the insulin, glucose and incretin hormone responses to a high protein meal with a high carbohydrate meal in people with KCNJ11 neonatal diabetes, people without diabetes and people with sulphonylurea-treated Type 2 Diabetes. To assess whether any effect seen is due to direct stimulation of the beta cell by the sulphonylurea itself, people with KCNJ11 neonatal diabetes will also undergo the same tests in the fasting state, having taken the sulphonylurea in the absence of any food.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥8yrs.
  • Willing and able to provide informed consent (adults i.e. participants aged >16 years).
  • Willing and able to provide assent and parents willing to provide informed consent (children and young people <16 years).

Exclusion criteria

  • Age <8yrs.
  • Unable/unwilling to provide informed consent (adults).
  • Unable/unwilling to provide assent (children) or parents unwilling to provide informed consent.
  • Known liver disease or chronic renal impairment (EGFR <60ml/min).

Treatment and study plan

High protein meal

Other

Breakfast with high protein / low carbohydrate content

High carbohydrate meal

Other

Breakfast with high carbohydrate / low protein content

Paracetamol

Drug

Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.

Other names: Acetaminophen

Fasting state - sulphonylurea only

Other

People with diabetes take sulphonylurea medication in the absence of any food stimulus

Primary outcomes

  1. Glucose levels

    Time frame: 240 minutes

    Glucose AUC after each meal.

  2. Insulin levels

    Time frame: 240 minutes

    Insulin AUC after each meal.

Secondary outcomes

  1. GLP-1 levels

    Time frame: 240 minutes

    GLP-1 AUC after each meal.

  2. GIP levels

    Time frame: 240 minutes

    GIP AUC after each meal.

  3. Glucagon levels

    Time frame: 240 minutes

    Glucagon AUC after each meal.

  4. Paracetamol levels

    Time frame: 240 minutes

    Rate of change of paracetamol levels after each meal as marker of gastric emptying.

Sponsors and collaborators

Lead sponsor

Royal Devon and Exeter NHS Foundation Trust

Other

Registry information

Official study title

Assessing the Effect of Food Composition on Postprandial Insulin Secretion in KCNJ11 Neonatal Diabetes (FoND Study)

Acronym: FoND

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Oct 3, 2016
Registry last updated
Oct 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.